May 15, 2011 Issue
Primary Prevention of CVD: Treating Dyslipidemia [Clinical Evidence Handbook]

What are the effects of pharmacologic cholesterol-lowering interventions in persons at low, medium, and high risk of CHD? What are the effects of a reduced- or modified-fat diet in persons at risk of CHD?

Mar 15, 2011 Issue
Considerations for Safe Use of Statins: Liver Enzyme Abnormalities and Muscle Toxicitiy [Article]

Statins play an important role in the care of patients with cardiovascular disease and have a good safety record in clinical practice. The risk of hepatic injury caused by statins is estimated to be about 1 percent, similar to that of patients taking a placebo. Patients with transaminase levels no m...

Feb 1, 2011 Issue
Should We Treat Moderately Elevated Triglycerides? No: Reducing Moderately Elevated Triglycerides Is Not Proven to Improve Patient Outcomes [Editorials: Controversies in Family Medicine]

Moderately elevated triglyceride levels have not been established as an independent risk factor for CHD. More importantly, the lowering of moderately elevated triglyceride levels with drug therapy has not been shown to decrease the rate of CHD for primary prevention in otherwise healthy individuals.

Feb 1, 2011 Issue
Should We Treat Moderately Elevated Triglycerides? Yes: Treatment of Moderately Elevated Triglycerides Is Supported by the Evidence [Editorials: Controversies in Family Medicine]

Nov 1, 2010 Issue
For Hyperlipidemia, Go Where the Evidence Takes You: Give a Statin and Nothing Else [Editorials: Controversies in Family Medicine]

Only statins have patient-oriented evidence supporting their role in reducing all-cause mortality. The NCEP–ATP III guidelines offer a nine-step approach for reaching target lipid levels, but the application to everyday practice is far simpler: If a patient with hyperlipidemia has coronary disease, prescribing a statin is the obvious choice.

Nov 1, 2010 Issue
The Role of Nonstatin Therapy in Managing Hyperlipidemia [Editorials: Controversies in Family Medicine]

When treating hyperlipidemia, physicians often face the question of the clinical value of nonstatin drugs, including bile acid sequestrants, fibrates (fibric acid derivatives), niacin, and cholesterol-absorption inhibitors. This editorial highlights the most prominent trial data and examines the mer...

Sep 1, 2010 Issue
Hyperlipidemia Treatment in Children: The Younger, the Better [Editorials: Controversies in Family Medicine]

Despite the absence of data in children demonstrating morbidity and mortality reduction by aggressive treatment of lipid disorders, the overwhelming data in adults (e.g., decreasing LDL cholesterol, improved morbidity and mortality) and evidence of atherosclerotic lesions developing in childhood support the argument for early treatment.

Sep 1, 2010 Issue
Screening for Hyperlipidemia in Children: Primum Non Nocere [Editorials: Controversies in Family Medicine]

Only 40 to 55 percent of children with elevated cholesterol and low-density lipoprotein levels will continue to have elevated lipids on follow-up. A recent evidence review supporting the U.S. Preventive Services Task Force statement on lipid screening in children reached the following conclusions: (...

Sep 1, 2010 Issue
Multiple Erythematous-Yellow, Dome-Shaped Papules [Photo Quiz]

Photo Quiz presents readers with a clinical challenge based on a photograph or other image.

May 1, 2010 Issue
Diet and Exercise in the Management of Hyperlipidemia [Article]

Dietary factors that influence lipid levels include modification of nutritional components, consumption of specific foods, use of food additives and supplements, and major dietary approaches. The most beneficial changes result from reducing intake of saturated and trans fats; increasing intake of po...

Pages: Previous 1 2 3 4 5 6 7 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now